Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

"The Once A Day Protease Inhibitor Regimens"

This study has been completed.
Information provided by (Responsible Party):
Roberto Arduino, The University of Texas Health Science Center, Houston Identifier:
First received: October 18, 2005
Last updated: December 12, 2013
Last verified: December 2013
Results First Received: May 2, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: HIV Infections
Interventions: Drug: ritonavir-boosted atazanavir
Drug: ritonavir-boosted fosamprenavir

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Atazanavir No text entered.
Fosamprenavir No text entered.
Total Total of all reporting groups

Baseline Measures
    Atazanavir   Fosamprenavir   Total
Overall Participants 
[units: participants]
 39   37   76 
[units: participants]
<=18 years   0   0   0 
Between 18 and 65 years   38   33   71 
>=65 years   1   4   5 
[units: years]
Mean (Standard Deviation)
 48  (9.7)   48  (10)   48  (10) 
[units: participants]
Female   11   9   20 
Male   28   28   56 
Region of Enrollment 
[units: participants]
United States   39   37   76 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Proportion of Patient With Viral Load Less Than 400 Copies/mL   [ Time Frame: 24 weeks ]

2.  Secondary:   CD4 Cell Count Change From Baseline During Treatment.   [ Time Frame: 24 weeks. ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
High porportion of subject did not complete the study.

  More Information